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The success of large-scale screening for Chlamydia trachomatis depends on the availability of noninvasive
samples, low costs, and high-quality testing. To evaluate C. trachomatis testing with pregnant women, first-void
urine specimens from 750 consecutive asymptomatic pregnant women from the Rotterdam area (The Nether-
lands) were collected. Initially, we investigated the performance of three different DNA isolation methods with
350 of these urines and 70 pools of 5 of the same subset of urine samples. The routinely used COBAS
AMPLICOR test was compared to the COBAS AMPLICOR test with prior DNA isolation by use of the MagNA
Pure large-volume kit and the MagNA Pure bacterial DNA isolation kit. The latter combination provided the
best DNA test for pooled urines, with a sensitivity twice that of the other methods. Next, using all 750 urines,
the COBAS AMPLICOR performance for individual testing was compared to pooled testing with the standard
COBAS AMPLICOR procedure and subsequently to pooled testing with COBAS AMPLICOR in combination
with the MagNA Pure bacterial DNA isolation kit. The sensitivity of COBAS AMPLICOR was 65% on
individual and 42% on pooled urines but improved to 92% on pooled urines with the MagNA Pure bacterial
DNA isolation kit, making this combination the best screening method. The C. trachomatis prevalence in this
population appeared to be 6.4%. Additionally, the cost of the combined MagNA Pure bacterial DNA isolation
kit and COBAS AMPLICOR method on pooled urines was only 56% of the cost of the standard COBAS
AMPLICOR test applied to individual urines. Costs per positive case detected in the combined method were
39% of standard costs.
Chlamydia trachomatis is one of the major sexually transmit-
ted pathogens, and high prevalences of chlamydial infection
have been documented for asymptomatic women in many Eu-
ropean countries (34). Asymptomatic carriers are of substan-
tial importance in the transmission of C. trachomatis infection
within a community. Asymptomatic chlamydial infection in
pregnant women imposes an additional risk for acute and
chronic consequences for the women themselves and their
(unborn) offspring (2, 6, 8, 9, 16). In The Netherlands, C.
trachomatis causes most sexually transmitted infections, with
approximately 60,000 new cases estimated for a total popula-
tion of 16 million in the year 2000. Studies in general practice
have shown an increase in the incidence of chlamydial infec-
tions (26), but data covering other specific target groups out-
side of the sexually transmitted disease (STD) outpatient clin-
ics are sparse (1). Dutch population-based screening for C.
trachomatis is still under debate, with cost-effectiveness of
screening, complexity of sampling, the reliability of test meth-
ods, and the nature of the target population as major issues of
discussion (23).
In order to investigate the prevalence of chlamydial infec-
tion during pregnancy in Rotterdam, and the risk factors and
consequences of chlamydial infection during pregnancy for
women and newborns, a follow-up study was planned. We
explored different methods for C. trachomatis testing with
respect to sensitivity and cost-effectiveness. The preferred
method for the detection of asymptomatic chlamydial infection
with a low threshold should involve urine specimens in com-
bination with nucleic acid amplification techniques (NAATs)
(33). However, bacterial loads in urine are generally low, which
has an adverse effect on the sensitivity of NAATs (25). Urines
of asymptomatic women generate inferior NAAT results,
sometimes 10% lower in sensitivity than attained for male
urines (10, 30). To reduce the costs of chlamydial screening in
low-prevalence populations, pooling of urine specimens has
been suggested. Although some studies suggested 100% sen-
sitivity of pooled testing compared to individual testing (7, 17),
other studies showed a lower sensitivity (14, 21), which de-
creased most significantly when eight or more urines were
pooled (13, 14). Another important aspect is that large-scale
screening programs require automation of test procedures,
which should simultaneously improve the quality of testing and
reduce the costs.
To date limited data are available concerning NAAT per-
formed on urines from (asymptomatic) pregnant women as
well as for NAAT for pooled urines. We present a report of a
study of 750 pregnant women in which the performance and
* Corresponding author. Mailing address: Department of Paediat-
rics, Erasmus MC—Sophia Children’s Hospital, Rotterdam, The
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costs of testing with both pooled urines and automated speci-
men preparation (using the MagNA Pure LC system and DNA
amplification with the COBAS AMPLICOR system) for the
detection of asymptomatic C. trachomatis infection were eval-
uated.
MATERIALS AND METHODS
Patient population. Pregnant women and their offspring were enrolled in the
Generation R study, a prospective multicenter, population-based cohort trial
that includes 10,000 children and their mothers in Rotterdam. The study focuses
on growth, development, and health of children from intrauterine fetal life to
adolescence (11). Pregnant women before 24 weeks of gestational age who were
Dutch residents and expected to deliver in the Rotterdam area were approached
to take part in the study. After informed consent was obtained, women were
asked for a fresh first-void urine specimen, preferably at a gestational age of 12
weeks. For the current study, 750 urine specimens were tested anonymously.
DNA amplification. Throughout the study, the automated C. trachomatis
COBAS AMPLICOR PCR system (10) (Roche Diagnostics, Almere, The Neth-
erlands) was used according to the manufacturer’s instructions to detect chla-
mydial DNA in specimens processed by any of the methods described below. Pos-
itive specimens were subjected to quantitative LightCycler PCR (version 3.5) to
assess the bacterial load (35). For this purpose, DNA was isolated from each
specimen according to method IIIB (see below). The PCR protocol was based on the
use of the FastStart DNA MasterPLUS SYBR Green I kit (Roche), the primers
5-GGACAAATCGTATCTCGG-3 and 5-GAAACCAACTCTACGCTG-3, and
40 amplification cycles. The same dilution range of C. trachomatis serovar E (100,
102, and 104 [relative C. trachomatis concentrations]) was included in each run
and used to calculate the concentration of target DNA relative to the initial copy
number in the undiluted control. Since this control was not subjected to titration, the
absolute number of bacteria could not be determined.
Processing of specimens. The 750 samples were analyzed in two separate
batches. Initially, a group of 350 samples was tested according to six different
protocols as outlined below and in Fig. 1 (methods IA to IIIB). Afterwards, all
750 samples were tested individually using COBAS AMPLICOR, tested in pools
of five according to the COBAS AMPLICOR procedure, and tested in pools of
five with preceding DNA purification by use of MagNA Pure bacterial DNA
isolation kit III.
Method IA: COBAS AMPLICOR procedure on individual urines. Single urine
specimens were processed according to the instructions of the COBAS
AMPLICOR manufacturer (Roche Diagnostics). In short, a 500-l urine spec-
imen was diluted with 500 l of washing buffer and centrifuged at 14,000 rpm.
The pellet was resuspended in 250 l of lysis buffer and centrifuged again after
addition of 250 l of diluent. The supernatant (50 l) was used for PCR. The
results were reported as negative or positive.
Method IB: COBAS AMPLICOR procedure on pooled urines. Pools for the
COBAS AMPLICOR were made by adding 100 l of five different urines into
one tube. The 500-l urine specimen was further processed as described above,
and 50 l of the supernatant was used for PCR. The urines from negative pools
were reported as negative. Urines from positive pools were individually retested
and reported as described for method IA.
Method IIA: MagNA Pure large-volume kit on individual urines. The
(MagNA Pure LC DNA Isolation Kit—Large Volume; Roche Diagnostics) was
used to isolate DNA from urines according to the manufacturer’s instructions.
From individual urines a 1,000-l specimen was used. DNA was isolated in the
automated MagNA Pure LC instrument using an elution volume of 100 l, of
which 25 l was used for PCR. The results were reported as negative or positive.
Method IIB: MagNA Pure large-volume kit on pooled urines. The MagNA
Pure large-volume kit (Roche Diagnostics) was used according to the manufacturer’s
instructions. Pools were made of five urines by adding 200 l of each of the five
urines into one tube. From these pools the full 1,000-l specimen was taken and
used without further processing. DNA was isolated in the automated MagNA Pure
LC instrument using an elution volume of 100 l, of which 25 l was used for PCR.
The urines from negative pools were reported as negative. Urines from positive
pools were individually retested and reported as described for method IIA.
Method IIIA: MagNA Pure bacterial DNA isolation kit on individual urines.
The MagNA Pure bacterial DNA isolation kit (MagNA Pure LC DNA Isolation
Kit III; Roche Diagnostics) was used to isolate DNA from individual urines.
From single urines 500 l was taken and centrifuged for 10 min at 14,000 rpm.
Subsequently 400 l was removed and the pellet was resuspended in 100 l of the
remaining supernatant, mixed with 130 l lysis buffer and 20 l proteinase K,
incubated for 10 min at 65°C, and denatured for 10 min at 95°C. Finally, DNA
was isolated in the automated MagNA Pure LC instrument using a sample
volume of 250 l and an elution volume of 100 l. Again, 25 l was used for
PCR. The results were reported as negative or positive.
Method IIIB: MagNA Pure bacterial DNA isolation kit on pooled urines. The
MagNA Pure LC Bacterial DNA Isolation Kit III (Roche Diagnostics) was used
to isolate DNA from pooled urines. Pools were made of five urines by adding 200
l of each of the five urines into one tube. From each pool the full 1,000 l was
taken and centrifuged for 10 min at 14,000 rpm. Subsequently 900 l was
removed, and the pellet was resuspended in 100 l of the remaining supernatant,
mixed with 130 l lysis buffer and 20 l proteinase K, incubated for 10 min at
65°C, and thereafter denatured for 10 min at 95°C. Finally, DNA was isolated in
the automated MagNA Pure LC instrument using a sample volume of 250 l and
an elution volume of 100 l. Again, 25 l was used for PCR. The urines from
negative pools were reported as negative. Urines from positive pools were indi-
vidually retested and reported as described for method IIIA.
Figure 1 summarizes the various volumes used in each test method. In meth-
ods IIA, IIB, IIIA, and IIIB, the elution buffer did not contain MgCl2 and
consequently could not be used directly in the PCR. Therefore, the eluate for
amplification was mixed 1:1 with MgCl2-containing diluent from the COBAS
AMPLICOR system. In the PCR 50 l of this mixture was used.
Discrepancy analysis. A specimen was considered to be truly positive if one or
more of the test methods described above gave results that were positive for
individual samples. When a pool was positive, all individual samples were re-
tested according to the same procedure as used for the pool in order to identify
the positive specimen(s). A positive pool result was considered to be truly
positive when one or more individual samples within the pool appeared to be
positive by either method. A positive pool result was considered to be a false
positive when none of the individual samples within the pool turned out positive.
A negative pool result was considered a true negative in the presence of a
positive internal inhibition control as included in the commercial COBAS
AMPLICOR kit. All individual samples and pooled samples were retested when
results were discrepant. When the internal control was negative, the sample
contained inhibitors. Retesting was performed after diluting the specimen 10-
fold and heating the sample for 10 min at 95°C.
Costs. We calculated the costs of materials and reagents for individual and
pooled testing by the standard COBAS AMPLICOR method and by COBAS
AMPLICOR in combination with the MagNA Pure bacterial DNA isolation kit.
We used list prices available at the time of the study. We assumed full runs for
each test method, which consist of 20 specimens plus a positive and a negative
control per run for the COBAS AMPLICOR and 32 MagNA Pure specimens.
We calculated total costs and costs per positive case detected. We also calculated
the costs per positive case using standard COBAS AMPLICOR for individual
urines versus the combination of COBAS AMPLICOR with the MagNA Pure
bacterial DNA isolation kit for pooled urines. This was done for hypothetical
prevalences in a population ranging between 1% and 10%. Calculations were
based on full runs and pools of five urines and the sensitivity determined for the
COBAS AMPLICOR method with individual urines and for the combined
method with pooled urines.
Statistical analysis. Binomial 95% confidence intervals (CI) were calculated
for the prevalences and sensitivities of the different DNA isolation methods.
McNemar’s test was used to compare the two methods. The nonparametric
Kruskal-Wallis H test was used to compare median results.
RESULTS
Comparison of three different DNA isolation methods. Fig-
ure 1 summarizes the results of the analysis of the initial 350
urine specimens. Individual urines processed according to
method IA, IIA, or IIIA scored positive in 15, 14, and 27 cases,
respectively. This equals sensitivities of 51.7, 48.3, and 93.1%
calculated on the basis of the number of true positives (n 
29). The specificity was 100% for all tests.
Nine pools were positive with the standard COBAS
AMPLICOR test method (method IB). The use of the MagNA
Pure large-volume kit also yielded 9 positive pools and the use
of the MagNA Pure bacterial DNA isolation kit resulted in 19
positive pools, which included the 9 pools that were positive by
the standard COBAS AMPLICOR test as well as by the
MagNA Pure large-volume kit. Including the MagNA Pure
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bacterial DNA isolation kit clearly provided the most sensitive
test method (McNemar’s test; P  0.01), with equal sensitivi-
ties when testing pooled urines compared to individual urines.
Comparison of the COBAS AMPLICOR method for indi-
vidual urines versus pooled urines. Pooling of urines was com-
pared to individual testing with the COBAS AMPLICOR
method on all 750 urines; results are summarized in Table 1.
Testing individual urines by the COBAS AMPLICOR
method yielded 31 positive test results out of 750 specimens,
resulting in an estimated prevalence for C. trachomatis of
4.1% among these pregnant women. Testing of pooled
urines by the COBAS AMPLICOR method resulted in 15
positive pools out of 150 pools. Subsequent individual test-
ing of the 75 urines from these 15 pools by the COBAS
AMPLICOR yielded 20 positive tests, which with a total of
750 urines resulted in an estimated prevalence of 2.7%.
Eleven specimens would have been reported falsely negative
when using the COBAS AMPLICOR test only on pooled
urines (11/730  1.5%), which proved the sensitivity of
standard processing of pooled urines by the COBAS
AMPLICOR method to be 65% compared to individual
testing of urines by the COBAS AMPLICOR method. The
number of truly positive samples was 48.
Performance of the MagNA Pure bacterial DNA isolation
kit with pooled urines. Pooled urines were tested using the
standard COBAS AMPLICOR method as described above,
and results were compared to the performance of the com-
bination of the COBAS AMPLICOR method with the
FIG. 1. Methods and results of individual and pooled testing by different DNA isolation methods. Sensitivity values marked with an asterisk
indicate that the MagNA Pure bacterial DNA isolation kit provided the best method for DNA processing (P  0.01 [McNemar’s test]), with equal
levels of sensitivity and specificity for pooled urines and individual urines. NR, not relevant.
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MagNA Pure bacterial DNA isolation kit (Table 1). All 750
urines were tested in pools of five urines. A total of 34 pools
tested positive by COBAS AMPLICOR after DNA isolation
was done with the MagNA Pure bacterial DNA isolation kit.
Subsequent testing of the 170 individual urine specimens
yielded 44 positive urines compared to 20 urines by the
standard COBAS AMPLICOR method (McNemar’s test; P
 0.001).
Two pools which were positive after DNA isolation with the
MagNA Pure bacterial DNA isolation kit could not be con-
firmed by individual testing of urines in either isolation method
and were considered false positives. One other pool was pos-
itive after DNA isolation by the MagNA Pure bacterial DNA
isolation kit, but the individual urines were negative. However,
one urine from this pool was positive in the standard COBAS
AMPLICOR assay for individual urines. Therefore, the pool/
urine result was considered to be a true positive.
Altogether, 48 urines were positive for C. trachomatis after
individual testing by the COBAS AMPLICOR method with or
without the prior use of the MagNA Pure bacterial DNA
isolation kit, revealing a prevalence of C. trachomatis infection
of 6.4% in this population.
When positive individual testing in either method as the gold
standard is considered, routine individual testing of urines with
the COBAS AMPLICOR method proved to have a sensitivity
of 65%. This sensitivity dropped to 42% when the COBAS
AMPLICOR method on pooled urines was used. However,
when using pooled urines with the combination of the COBAS
AMPLICOR method after initial DNA isolation was done with
the MagNA Pure bacterial DNA isolation kit, the sensitivity
was 92% (see Table 1 for exact figures).
Inhibition. The COBAS AMPLICOR procedure showed
inhibition for one (0.7%) of the pools and for 37 (4.9%) of the
individually tested urines. After DNA isolation by MagNA
Pure LC procedures, no (0%) inhibition was found among
pooled urines and inhibition was found only once (0.6%) while
testing individual urines.
Bacterial load in pools. Positive urine specimens were sub-
jected to quantitative LightCycler PCR to assess the bacterial
load. Figure 2 illustrates the relative Chlamydia trachomatis
DNA concentrations of pooled urines observed with the use of
the LightCycler PCR in relation to the standard COBAS
AMPLICOR test results. True positive pools which tested neg-
ative by the standard COBAS AMPLICOR method had sig-
nificantly lower relative C. trachomatis concentrations than
positive pools (Kruskal-Wallis H test; P  0.001), confirming
that bacterial titers do contribute significantly to the sensitivity
of testing. Figure 3 illustrates the relative frequency distribu-
tions of the bacterial loads established in the urine samples
obtained from these essentially symptom-free females. Note
that most of the loads are relatively low but that no correlation
with the bacterial load in urine samples from symptomatic
patients has been made.
Costs. The Dutch costs for a COBAS AMPLICOR test was
10.33 euros per sample (isolation, 0.82 euro; amplification, 4.71
euros; detection, 4.80 euros) and for the MagNA Pure isola-
tion was 4.04 euros per sample with a full run. The cost of the
combined method (isolation with the MagNA Pure and sub-
sequent amplification plus detection by COBAS AMPLICOR)
was 13.55 euros. The total costs for 750 specimens were, there-
FIG. 2. Relative Chlamydia trachomatis (CT) concentrations of
pooled urines observed via LightCycler in relation to standard COBAS
AMPLICOR test results. Horizontal lines represent the medians of the
relative C. trachomatis concentrations of pooled urines. , P value
(Kruskal-Wallis H test).
FIG. 3. Relative Chlamydia trachomatis (CT) concentrations versus
numbers of patients falling in different titer classes. Note that most
patients fall within the low-titer classes.
TABLE 1. Test results and costs of individual and pooled urines by different DNA isolation methods
Procedure No. of positivetests/no. tested
No. of positive-
testing women/
no. tested
% Estimated
prevalence
(95% CI)
% Estimated
sensitivity
(95% CI)
Total cost
(euros)
Cost per case
detected
(euros)
COBAS AMPLICOR
Individual urines 31/750 31/750 4.1 (2.8–5.8) 65 (49–78) 8,522 275
Pooled urines 15/150 20/750 2.7 (1.6–4.1) 42 (28–57) 2,562 128
MagNA Pure bacterial DNA isolation kit
Pooled urines 34/150 44/750 5.9 (4.3–7.8) 92 (80–98) 4,770 108
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fore, 8,522 euros for the COBAS AMPLICOR method with
individual urines (750 tested with 75 controls) and 2,562 euros
when pooled testing by COBAS AMPLICOR was followed by
individual testing (150 pools with 15 controls plus 15 positive
pools times 5 individual tests with 8 controls, making 248 tests).
The costs for pooled and individual urines with the prior use of
the MagNA Pure bacterial DNA isolation kit were 4,770 euros
(150 pools with 15 controls plus 34 positive pools times 5
individual urines with 17 controls, making 352 tests). The cal-
culation of screening cost per positive detected case of C.
trachomatis infection incorporated the sensitivities found in
this study: 65% for the COBAS AMPLICOR test for individ-
ual urines, 42% for the COBAS AMPLICOR for pooled
urines, and 92% for the use of the MagNA Pure bacterial DNA
isolation kit in combination with the COBAS AMPLICOR
PCR test for pooled urines. Screening costs per positive de-
tected case were lowest with the use of the latter combination
(Table 1).
Figure 4 illustrates the difference in costs between standard
COBAS AMPLICOR used for individual urines compared to
the use of the MagNA Pure bacterial DNA isolation kit in
combination with the COBAS AMPLICOR PCR test for
pooled urines for hypothetical prevalences ranging from 1% to
10%.
DISCUSSION
Technological aspects. We analyzed 750 individual urine
samples by several methods. Overall, 31 samples tested posi-
tive upon individual testing using the COBAS AMPLICOR
platform. When pooled urines were used without prior DNA
purification the sensitivity of the test dropped significantly;
only 20 women tested positive. However, upon usage of the
MagNA Pure DNA isolation system, an overall number of 48
women tested truly positive (see Table 1 for a summary). So
this study shows that pooling of urines combined with prior
DNA isolation by use of the MagNA Pure bacterial DNA
isolation kit is a reliable and cost-effective way to both increase
the sensitivity of testing (by 27%) and decrease the costs per
detected case (by 62%) during large-scale testing for asymp-
tomatic C. trachomatis infection among pregnant women. Fur-
thermore, we show a 6.4% prevalence of C. trachomatis car-
riage in apparently healthy pregnant women in this Dutch area.
We used the COBAS AMPLICOR test in our study because
it is fully automated and its performance is good (10, 28, 30,
32), being less prone to experimental variation than the
AMPLICOR test (19, 22). However, the sensitivity of COBAS
AMPLICOR for female urines is in the range of 80 to 90%, as
has been shown in STD outpatient populations (10, 30). A
major problem with the use of urine specimens is inhibition.
Urinalysis has shown that various substances are responsible
for inhibition (15) and that between 2% and 4% of urine
specimens contain inhibitors (4, 28). The sensitivity, however,
could be improved by using a modified specimen-processing
procedure (18). In our study the inhibition was slightly higher
when using the COBAS AMPLICOR method for individual
urines (4.9%) but much lower when using the same method for
pooled urines (0.7%). However, automated DNA isolation
from urines by use of the MagNA Pure Bacterial DNA Isola-
tion Kit prior to COBAS AMPLICOR reduced the inhibition
significantly in both individual and pooled testing. This signif-
icantly improved the sensitivity of C. trachomatis detection. In
addition, the use of the MagNA Pure bacterial DNA isolation
kit prior to COBAS AMPLICOR resulted in higher sensitivity
than automated DNA isolation with the MagNA Pure large-
volume kit, which may be explained by the additional use
of proteinase K prior to DNA isolation in the bacterial DNA
Kit.
Sample pooling and cost aspects. Pooling of urines is im-
portant to reduce the costs of screening. However, some de-
scribe a significant reduction of the sensitivity (7, 17), whereas
others reported a similar sensitivity with pooling (13, 14, 21). In
our study, pooling with the COBAS AMPLICOR method re-
sulted in a significant reduction of the sensitivity, which is
probably due to the dilution of positive specimens and—as
shown—not to the introduction of inhibitors from other urines
in a pool. However, the use of the MagNA Pure bacterial DNA
isolation kit restored and even improved the sensitivity. The
combined procedure was the only method producing accept-
able results with pooled urines. Therefore, pooling of urines in
large screening programs for the detection of asymptomatic C.
trachomatis infections should only be used in conjunction with
DNA isolation methods that yield highly purified DNA. It
should be noted that the sensitivity of our procedure was 92%
and not 100%. A low copy number of chlamydial targets in
positive urine specimens in our population of asymptomatic
women—as shown in Fig. 2—can explain this. Other variables
influencing the sensitivity are the quality of specimens and the
timing of sampling (5). The sensitivity of screening could be
improved by testing multiple specimens obtained at various
time points, but this would compromise the cost-benefit ratio
of screening programs.
C. trachomatis screening among pregnant women. Pregnant
women could be a specific target group for C. trachomatis
screening. Antenatal screening, as recommended by the Cen-
ters for Disease Control and Prevention (3), may be beneficial
for decreasing morbidity among women themselves but also to
prevent vertical (infant) and horizontal (partner) transmission
(2, 6, 8, 9, 24). Screening of pregnant women usually yields
prevalences similar to those obtained with nonpregnant
women. In Europe, the prevalence of C. trachomatis infection
FIG. 4. Costs per positive Chlamydia trachomatis case detected
in relation to population prevalences. F, COBAS AMPLICOR re-
sults for individual urines; ■, pooled MagNA Pure plus COBAS
AMPLICOR results.
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among asymptomatic women was recently estimated to range
from 1.7% to 17%, depending on setting, context, and country
(34). The prevalence of 6.4% for apparently healthy pregnant
Dutch women is much higher than previously reported for
asymptomatic women in general practices (2.9% and 4.9% in
1996 and 1997) or in a general obstetric and gynecological
population (4.5% in 2002) (1, 27, 31) and approaches the
chlamydial prevalence of 7.3% that was found in 1998 among
women consulting the STD outpatient clinic in Rotterdam
(29). However, these figures must be interpreted with caution
since test format is clearly important. Testing of individual
urines by the COBAS AMPLICOR method without prior
DNA isolation by the MagNA Pure bacterial DNA isolation kit
yielded a much lower prevalence of 4.1%.
Screening programs are considered to be cost-effective when
the prevalence of C. trachomatis infection is higher than 3 to
6% (12, 20, 23, 33). The introduction of improved techno-
logy for screening may reveal higher prevalences, render-
ing screening programs cost-effective. It was shown that
COBAS AMPLICOR testing was more cost-effective with
pooled urines compared to individual urines, but pooling
reduced sensitivity. However, usage of the MagNA Pure
bacterial DNA isolation kit increased sensitivity and ap-
peared to be more cost-effective: the calculated costs per
detected case in the combined method with pooling were a
mere 39% of the costs of individual testing with COBAS
AMPLICOR.
In conclusion, we show that pooled testing for C. trachomatis
infection in asymptomatic pregnant women can be developed
for large-scale testing provided that the COBAS AMPLICOR
method is used together with prior chlamydial DNA isolation
by use of the MagNA Pure bacterial DNA isolation kit. This
combination significantly improves sensitivity and decreases
costs.
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